Przegląd Dermatologiczny

Full text

1/2026 vol. 113
Original article

Minocycline-Associated Pseudotumor Cerebri: Neurological Implications in Dermatological Practice

Anood Al-Issa 1, 2

  1. Dr Anood Alissa Clinic, Amman, Jordan

  2. The Specialty Hospital, Amman, Jordan


Dermatol Rev/Przegl Dermatol 2026, 113, 8–12

DOI: https://doi.org/10.5114/dr.2026.162087
Data publikacji online: 2026/06/05
Article file
minocycline.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Karahalios D.G., Rekate H.L., Khayata M.H., Apostolides P.J.: Elevated intracranial venous pressure as a universal mechanism in pseudotumor cerebri of varying etiologies. Neurology 1996, 46, 198-202.
  2. King J.O., Mitchell P.J., Thomson K.R., Tress B.M.: Manometry combined with cervical puncture in idiopathic intracranial hypertension. Neurology 2002, 58, 26-30.
  3. Chiu A.M., Chuenkongkaew W.L., Cornblath W.T., Trobe D., Digre K.B., Dotan S.A., et al.: Minocycline treatment and pseudotumor cerebri syndrome. Am J Ophthalmol 1998, 126, 116-121.
  4. Mochizuki K., Takahashi T., Kano M., Terajima K., Hori N.: Pseudotumor cerebri induced by minocycline therapy for acne vulgaris. Jpn J Ophthalmol 2002, 46, 668-672.
  5. Kesler A., Goldhammer Y., Hadayer A., Pianka P.: The outcome of pseudotumor cerebri induced by tetracycline therapy. Acta Neurol Scand 2004, 110, 408-411.
  6. Kaabour M., Guerisse F., Mols P., Levy S.: Pseudotumeur cérébrale due à la prise de minocycline [Pseudotumor cerebri due to taking minocycline]. Rev Med Brux 2017, 38, 169-172.
  7. Monaco F., Agnetti V., Mutani R.: Benign intracranial hypertension after minocycline therapy. Eur Neurol 1978, 17, 48-49.
  8. Giles C.L., Soble A.R.: Intracranial hypertension and tetracycline therapy. Am J Ophthalmol 1971, 72, 981-982.
  9. Stuart B.H., Litt I.F.: Tetracycline-associated intracranial hypertension in an adolescent: a complication of systemic acne therapy. J Pediatr 1978, 92, 679-680.
  10. Walters B., Gubbay S.: Tetracycline and benign intracranial hypertension: report of 5 cases. BMJ 1981, 282, 19-20.
  11. Pearson M.G., Littlewood S.M., Bowden A.N.: Tetracycline and benign intracranial hypertension. BMJ 1981, 282, 568-569.
  12. Pierog S.H., Al-Salihi F.L., Cinotti C.: Pseudotumor cerebri: a complication of tetracycline treatment for acne. J Adolesc Health Care 1986, 7, 139-140.
  13. Quinn A.G., Singer S.B., Buncic J.R.: Pediatric tetracycline-induced pseudotumor cerebri. J AAPOS 1999, 3, 53-57.
  14. Garner S.E., Eady A., Bennett C., Newton J.N., Thomas K., Popescu C.M.: Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2012, 2012, CD002086.
  15. Bababeygy S., Repka M.X., Subramanian P.S.: Minocycline-associated pseudotumor cerebri with severe papilledema. J Ophthalmol 2009, 2009, 203583.
  16. Lucia R., Oliveira-Filho R.M., eds.: Farmacologia Integrada. 2nd ed. Revinter, Rio de Janeiro, 2004, 678.
  17. Prieto-Diaz J., Souza-Dias C.: Estrabismo. 2nd ed. Roca, Barcelona, 1986, 440.
  18. Jukes T.H.: Some historical notes on chlortetracycline. Rev Infect Dis 1985, 7, 702-707.
  19. Jonas M., Cunha B.A.: Minocycline. Ther Drug Monit 1982, 4, 137-145.
  20. Graber E.M.: Treating acne with the tetracycline class of antibiotics: a review. Dermatol Rev 2021, 2, 321-330.
  21. Zhanel G., Critchley I., Lin L.Y., Alvandi N.: Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris. Antimicrob Agents Chemother 2018, 63, e01318.
  22. Chopra I., Roberts M.: Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001, 65, 232-260.
  23. Garrido-Mesa N., Zarzuelo A., Galvez J.: Minocycline: far beyond an antibiotic. Br J Pharmacol 2013, 169, 337-352.
  24. Redin G.S.: Antibacterial activity in mice of minocycline, a new tetracycline. Antimicrob Agents Chemother 1966, 6, 371-376.
  25. Solodyn (Minocycline Hydrochloride) Extended Release Tablets. [Accessed on 13 June 2021]. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/050808s000TOC.cfm
  26. Minocycline (Topical). [Accessed on 18 February 2021]. Available online: https://www.drugs.com/monograph/minocycline-topical.html
  27. Sapadin A.N., Fleischmajer R.: Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006, 54, 258-265.
  28. Bikowski J.B.: Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2003, 2, 234-245.
  29. Gether L., Overgaard L.K., Egeberg A., Thyssen J.P.: Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol 2018, 179, 282-289.
  30. Buddenkotte J., Steinhoff M.: Recent advances in understanding and managing rosacea. F1000Res 2018, 7, F1000.
  31. Farshchian M., Daveluy S.: Rosacea. StatPearls; Treasure Island, FL, USA 2020.
  32. Huynh T.T.: Burden of disease: the psychosocial impact of rosacea on a patient’s quality of life. Am Health Drug Benefits 2013, 6, 348-354.
  33. Medgyesi B., Dajnoki Z., Beke G., Gaspar K., Szabo I.L., Janka E.A., et al.: Rosacea is characterized by a profoundly diminished skin barrier. J Investig Dermatol 2020, 140, 1938-1950.
  34. Darlenski R., Kazandjieva J., Tsankov N., Fluhr J.W.: Acute irritant threshold correlates with barrier function, skin hydration and contact hypersensitivity in atopic dermatitis and rosacea. Exp Dermatol 2013, 22, 752-753.
  35. Powell F.C., Ni Raghallaigh S.: Interventions for ‘rosacea’. Br J Dermatol 2011, 165, 707-708.
  36. Bhate K., Williams H.C.: Epidemiology of acne vulgaris. Br J Dermatol 2013, 168, 474-485.
  37. Tan A.U., Schlosser B.J., Paller A.S.: A review of diagnosis and treatment of acne in adult female patients. Int J Womens Dermatol 2018, 4, 56-71.
  38. Zaenglein A.L., Pathy A.L., Schlosser B.J., Alikhan A., Baldwin H.E., Berson D.S., et al.: Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016, 74, 945-973.
  39. Goodman G.: Acne and acne scarring – the case for active and early intervention. Aust Fam Physician 2006, 35, 503-504.
  40. Karadag A.S., Aslan Kayiran M., Wu C.Y., Chen W., Parish L.C.: Antibiotic resistance in acne: changes, consequences and concerns. J Eur Acad Dermatol Venereol 2021, 35, 73-78.
  41. Myers S.A., Wolowacz R.G.: Tetracycline-based MMP inhibitors can prevent fibroblast-mediated collagen gel contraction in vitro. Adv Dent Res 1998, 12, 86-93.
  42. van der Linden M.M.D., van Ratingen A.R., van Rappard D.C., Nieuwenburg S.A., Spuls P.I.: DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Br J Dermatol 2017, 176, 1465-1474.
  43. Kircik L.H.: Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications. J Drugs Dermatol 2010, 9, 1407-1411.
  44. Sunderkötter C., Becker K.: Systemtherapie mit Antiinfektiva. Übersicht über wichtige Antibiotika in der Dermatologie [Systemic therapy with antibiotics. Overview of important antibiotics in dermatology]. Hautarzt 2014, 65, 113-124.
  45. Mavranezouli I., Daly C.H., Welton N.J., Deshpande S., Berg L., Bromham N., et al.: A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris. Br J Dermatol 2022, 187, 639-649.
  46. Harrison P.V.: A comparison of doxycycline and minocycline in the treatment of acne vulgaris. Clin Exp Dermatol 1988, 13, 242-244.
  47. Toossi P., Farshchian M., Malekzad F., Mohtasham N., Kimyai-Asadi A.: Subantimicrobial-dose doxycycline in the treatment of moderate facial acne. J Drugs Dermatol 2008, 7, 1149-1152.
  48. James W.D., Berger T.G., Elston D.M.: Andrews’ Diseases of the Skin: Clinical Dermatology. 13th ed. Elsevier, Philadelphia, 2019, 1280.
  49. Oge L.K., Broussard A., Marshall M.D.: Acne vulgaris: diagnosis and treatment. Am Fam Physician 2019, 100, 475-484
Copyright: © 2026 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Indeks osobowy
Share
without publication fees
without publication fees
Coverage in
Integrated with
plagiat pl
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications